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The solubility of three drugs (glimepiride, pioglitazone, sibutramine) with different acid/base 
properties and expected supersaturation behavior was examined in detail using the shake-flask (SF) 
and potentiometric (CheqSol) methods. Both uncharged (free) species and hydrochloride salts were 
used as starting materials. On the one hand, the SF method provided information about the 
thermodynamic solubility at any pH value, including the counterion-dependent solubility of ionic 
species. Additionally, this method easily allowed the identification of the solid phase in equilibrated 
solutions by powder X-ray diffraction, and the detection and quantification of aggregation and 
complexation reactions. On the other hand, CheqSol method permitted the measurement of the 
equilibrium solubility of neutral species, the observation of changes in solid forms, and the extent and 
duration of supersaturation (kinetic solubility) for “chaser” compounds. The combined information 
from both methods gave an accurate picture of the solubility behavior of the studied drugs. 
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Solubility is a fundamental physicochemical property affecting the bioavailability of potential 
drug candidates, especially those intended for oral administration. Together with permeability, 
solubility is used in the Biopharmaceutics Classification System (BCS) to describe the behavior of a 
drug (Amidon et al., 1995). Several methods are available for the determination of solubility, which 
might be especially convenient at different stages of the drug discovery process (Avdeef, 2012; Di et 
al., 2012; Veseli et al., 2019). For instance, high-throughput methods based on DMSO solutions of 
drug added to aqueous buffer, followed by light scattering/turbidity or UV plate reader detection 
systems are adequate for early stages, but more accurate (and low-throughput) approaches are 
required for late stage discovery candidates. Among these latter ones, the shake-flask (SF) method is 
the “gold standard”. Sample is added into a flask and dissolved in an aqueous buffer until the presence 
of an excess solid. Then the flask is shaken (or stirred) for a long time allowing equilibration between 
solid and saturated solution. According to the recommendations of regulatory agencies (EMA, 2018; 
FDA, 2017), several pH conditions should be evaluated in order to define the pH-solubility profile of 
the drug within range of 1-6.8, corresponding to the pH variations in the upper gastrointestinal tract. 
These guidelines also foresee alternative methods with proven ability to predict the equilibrium 
solubility of the test drug substance, such as the CheqSol potentiometric titration method (Box et al., 
2006; Stuart and Box, 2005).  
In the CheqSol method the sample is completely dissolved at a certain pH in order to ensure the 
compound in its more soluble charged species (acidic medium for bases, BH+; alkaline for acids, A-
). Then the solution is titrated with strong base or acid until a first precipitate is induced and optically 
detected, followed by alternate back-titration cycles between fully dissolved and precipitating 
solutions, which finally allows the calculation of solubility from mass and charge balances, and pH 
measurements (Box et al., 2009).  
The present study is focused on the accurate characterization by SF and CheqSol methods of 
the solubility behavior of three different drugs (glimepiride, pioglitazone, and sibutramine) and the 
effect of the starting solid (free species or salt). In fact, both procedures not only provide information 
about the thermodynamic solubility of the neutral compound (intrinsic solubility), but also on 
different features relevant for understanding the solubility process of the drug (Table 1). From the 
measured pH and the added titrant volumes, the potentiometric method calculates the concentration 
of the drug in solution. The method can estimate the extent and duration of supersaturation, which 
might be very relevant parameters for the bioavailability of an orally administered drug beyond its 
thermodynamic solubility. The SF method easily allows the collection of the precipitate after phase 
separation, and thus the identification by powder X-ray diffraction (PXRD) of the solid in equilibrium 
at a particular pH value. This is especially relevant because the particular form of the solid, which 
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plays a key role in the solubility of active pharmaceutical ingredient, clearly depends on the pH 
(precipitation of uncharged “free” species or salt comprising the drug) and ionized forms on the 
counterions present in the buffered solution. 
The three studied drugs show different acid-base behavior. Glimepiride, pioglitazone and 
sibutramine are, respectively, an acid, an ampholyte and a base, each expected to show distinctive 
solubility-pH profiles. Two different computer programs, ACD/Labs (Advanced Chemistry 
Development, Canada) and pDISOL-X (in-ADME Research, USA), were used to predict these 
profiles from the molecular structure of the compounds, and the results are presented in Figure 1. 
Similar plots were obtained for glimepiride, but differences in solubility were clear for pioglitazone, 
and a difference of 1 unit was observed for the predicted pKa of sibutramine depending on the program 
used. In addition to their ionization features, these drugs have different molecular properties and 
therapeutic indications or mechanisms of action. Sibutramine was used for the treatment of obesity 
until 2010. It is the smallest of the three studied drugs, showing poor hydrogen-bonding capabilities 
and a highly reduced polar surface area. In contrast, glimepiride is a polar antidiabetic drug with a 
sum of 12 hydrogen-bond acceptors/donors and a molecular weight of nearly 500. The antidiabetic 
pioglitazone exhibits molecular properties in between of sibutramine and glimepiride, with the 
exception of a relative high contribution of polar atoms and their attached hydrogens (Table 2 and 
Fig. 1). Since supersaturation in aqueous solution is expected for molecules with high polar surface 
and a sum of at least three hydrogen-bond donors and acceptors (Box et al., 2009), it is of interest to 
study this property for glimepiride and pioglitazone using the CheqSol method. On the contrary, the 
base sibutramine is not expected to show a significant supersaturation.  
 
2. Material and methods 
2.1. Chemicals and reagents  
Glimepiride (> 99%), pioglitazone (> 99%), sibutramine (> 99%) and the hydrochloride salt of 
pioglitazone and sibutramine (> 99%) were provided by the Polymorphism and Calorimetry Unit of 
the Scientific and Technological Centers of University of Barcelona (CCiT-UB). Acetic acid (> 99%), 
trifluoroacetic acid (min 99.0%), dimethylsulfoxide (> 99%), hydrochloric acid 1 M Titrisol, sodium 
hydroxide 1 M Titrisol, potassium hydroxide 1 M Titrisol, and methanol (HPLC gradient grade) were 
from Merck (Darmstad, Germany). Ethylenediamine (min 98.8%), potassium chloride (> 99%), 






pKa and potentiometric intrinsic solubility assays were performed using the GLpKa and PCA 
200 titrators from Sirius Analytical Instruments Ltd. (Forest Row, UK). Both instruments include a 
D-PAS probe, a bifurcated fibre-optic dip probe from Hellma Analytics (Müllheim, Germany) with 
path length of 1 cm, and a two channels solvent degasser from SMI-LabHut Ltd. (Churcham, UK). 
The operation of the apparatus was controlled by a personal computer running the Refinment Pro 2 
and the CheqSol software.  
SF experiments were performed using a Movil-ROD rotation shaker from Selecta (Abrera, 
Spain) in closed test tubes at 25 ºC. pH was measured using a Crison 5014 combined electrode 
connected to a GLP 22 potentiometer from Crison (Alella, Spain) calibrated with standard aqueous 
solutions (pH 7.00 and 4.01 or 9.21). After equilibration, phases were separated using a Rotanta 
460RS centrifuge from Hettich Lab Technologies (Tuttingen, Germany) for 30 min at 3500 rpm and 
25 ºC. Solubility was quantified by liquid chromatography using a Shimadzu Nexera UPLC system 
with two LC-30AD pumps, a DGU-20A5 online degasser, a SIL-30AC autosampler, a SPD-M20A 
diode array detector, a CTO-10ASvp oven at 25 ºC, and a CBM-20Alite controller. A 1.7 μm, 50 x 
2.1 mm Waters (Milford, MA, USA) Acquity BEH C18, 50 mm x 2.1 mm column was employed, at 
a flow rate of 0.5 mL min-1 and injection volume of 0.2 μL. Mobile phases consisted of methanol and 
aqueous 0.1 M formic acid pH 3.0. 
Powder X-ray diffraction characterization was performed using a PANalytical X’Pert PRO 
MPD / diffractometer of 240 millimetres of radius in transmission configuration using Cu Kα1+2 
radiation (λ = 1.5406 Å) with a focusing elliptic mirror and a PIXcel detector working at a maximum 
detector’s active length of 3.347. Configuration of convergent beam with a focalizing mirror and a 
transmission geometry with flat sample sandwiched between low absorbing films measuring from 1 
to 40 in 2θ, with a step size of 0.026 and measuring times of 75 or 300 seconds per step. 
Differential scanning calorimetry analysis was carried out by means of a Mettler-Toledo DSC-
822e calorimeter. Experimental conditions: aluminium crucibles of 40 µL volume, atmosphere of dry 
nitrogen with 50 mL/min flow rate, heating rate of 10ºC/min. The calorimeter was calibrated with 
indium of 99.99% purity. 
Thermogravimetric analysis was performed on a Mettler-Toledo TGA-851e thermobalance. 
Experimental conditions: alumina crucibles of 70 µL volume, atmosphere of dry nitrogen with 50 
mL/min flow rate, heating rate of 10ºC/min. 
 
2.3. pKa determination by spectrophotometric method  
Due to the very low solubility of the studied compounds, pKa values were 
spectrophotometrically determined using the methodology described in the current literature (Tam 
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and Takács-Novák, 2001). Briefly, 30 or 40 µL of stock solution (10 mM of compound in DMSO) 
and 250 µL of a 15 mM potassium phosphate buffer were added to 10 mL of a 0.15 M KCl ionic 
strength adjusted (ISA) aqueous solution. The pH of the sample was initially selected to titrate from 
low to high pH for basic compounds and high to low pH for acidic ones to avoid precipitation. Titrants 
were 0.5 M potassium hydroxide and 0.5 M hydrochloric acid. When the compound was not soluble 
enough in water, pKa was determined in different methanol/water mixtures and the aqueous pKa was 
obtained by extrapolation using Yasuda-Shedlovsky equation (Avdeef et al., 1993). All 
measurements were performed at least in triplicate at 25 ± 0.1 oC under nitrogen atmosphere. The 
collected data was refined through the Refinement Pro 2 software and the pKa values were obtained 
by target factor analysis (Tam and Takács-Novák, 2001). 
 
2.4. Solubility determination by CheqSol method  
Suitable amounts of sample (between 5 and 40 mg) were accurately weighed into the titration 
vessel and 10 mL of ISA solution were added. The pH value was adjusted with the suitable titrant 
(0.5 M hydrochloric acid or 0.5 M potassium hydroxide) to a value where the sample was fully ionized 
and thus completely dissolved. Then, samples were automatically back titrated until precipitation was 
induced, followed by the alternate cycles of subsaturation and supersaturation. Intrinsic solubility was 
determined from the pH in the chasing equilibrium points (cheqpoints) where equilibrium was 
reached as described elsewhere (Stuart and Box, 2005). All measurements were performed at least in 
quadruplicate at 25 ± 0.1 oC under argon atmosphere. 
 
2.5. Solubility determination by shake-flask method  
The recommended (Avdeef et al., 2016) Mass Spectrometry-Friendly Minimalist Universal 
Buffer (MS-MUB), consisting of 25 mM acetic acid, 25 mM ethylenediamine, and 75 mM 
trifluoroacetic acid (TFA), was used to prepare buffers between pH 1.8 and 12.0 for the determination 
of solubility-pH profiles. The desirable pH was adjusted by 0.5 M NaOH or 0.5 M HCl. The average 
buffer capacity and ionic strength of the pH buffers were 8.3mM/pH and 0.096M, respectively (in the 
absence of added sample). At each pH buffer, at least three aliquots were prepared by adding enough 
solid sample to obtain a saturated solution in 3 mL of the buffer solution. The incubation was carried 
out at controlled temperature (25 ± 0.1 oC) for 48 h (24 h stirring and 24 h sedimentation). The pH 
was measured after 4h of stirring and readjusted if necessary with sodium hydroxide or hydrochloric 
acid, and finally the pH was measured again before the phase separation by centrifugation. The 
concentration of sample in the supernatant was determined by liquid chromatography, whereas the 
solid was vacuum filtered and dried for at least 30 min to determine its crystal form by PXRD. 
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2.6. Refinement of intrinsic and salt solubility and aggregation constants 
The SF solubility data analysis method uses log S - pH as measured input data (along with the 
standard deviations in log S) for the pDISOL-X computer program, as described previously (Avdeef, 
2018; Marković et al., 2019; Völgyi et al., 2013). Briefly, an algorithm was developed which 
considers the contributions of all species present in solution, including all components of buffers or 
mixtures thereof. The approach does not assume that the traditional Henderson-Hasselbalch equations 
are valid. The computational algorithm derives its own implicit equations internally, given any 
practical number of equilibria and estimated constants. The constants can be subsequently refined by 
weighted nonlinear least-squares regression. Drug-salt precipitates, -aggregates, -complexes, -bile 
salt and -surfactant (Avdeef, 2018) species can be modeled. The presence of specific drug-buffer 
(Marković et al., 2019) species can be tested. The computer program calculates the distribution of 
species corresponding to a sequence of additions of acid titrant (e.g., HCl, or ionizable titrants, such 
as H3PO4) to simulate the speciation in the suspension down to pH ~ 0. Subsequently, a sequence of 
perturbations with a strong base (e.g., NaOH) is simulated, with the solubility calculated at each point 
(in pH steps of 0.005-0.2), up to pH ~ 13. The ionic strength is rigorously calculated at each step, and 
pKa values (as well as solubility products, aggregation constants) are accordingly adjusted. At the end 
of the speciation simulation, the calculated log S vs. pH curve is compared to measured log S vs. pH.  
A log S-weighted nonlinear least squares procedure refines the proposed equilibrium model, using 
analytical expressions for the differential equations. The process is repeated until the differences 
between calculated and measured log S values reach a minimum. 
 
3. Results and discussion 
3.1. Solubility by CheqSol method  
In order to determine the intrinsic solubility (S0) of the studied drugs by the potentiometric 
method, it was first necessary to measure accurately the corresponding pKa values (section 2.3). The 
determined acidity constants are reported in Table 3.  
For the base sibutramine and the ampholyte pioglitazone two different starting solids were 
considered in the solubility experiments, the free neutral species and their hydrochloride salts (in the 
case of glimepiride, because of its acidic nature, only the free acid was assayed). No significant 
differences were found in the measured intrinsic solubility (S0, that of the neutral species) of each 
compounds depending on the particular solid form initially weighed, which is not unexpected 
provided that the CheqSol method involves the complete dissolution in the ionized form before the 
beginning of the titration procedure. Determined intrinsic solubilities are reported in Table 3, and in 
the cases of glimepiride and pioglitazone they are consistent with literature values also 
potentiometrically determined. 
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In addition to the thermodynamic solubility of the neutral species (S0) and in contrast to SF 
method, CheqSol provides valuable information about supersaturation of the studied molecules (Box 
et al., 2009). Figure 2 shows the Bjerrum Curves (Avdeef, 1998) (left panels) and the neutral species 
concentration-time profiles along time course (right panels) for the three drugs. The Bjerrum plots 
show the theoretically expected changes in the protonation state (molecular charge) caused by 
ionization in absence (solution curve) or in presence of precipitation, together with experimental data 
points. In the beginning of glimepiride and pioglitazone titrations (left panels in Figs. 2A and 2B), 
starting at basic pH, the measured data follow the solution Bjerrum curve. Due to supersaturation this 
solution curve is followed beyond the pH needed to start precipitation (crossing of solution and 
precipitation curves), and when the solid starts precipitating the data points come closer to the 
precipitation curve. Finally, the chasing equilibrium around the precipitation curve takes place, 
consisting of flips between induced supersaturated and subsaturated states by alternate additions of 
acidic and basic titrant. Thus, both glimepiride and pioglitazone show a chaser behavior, and the 
variations on the concentration of the neutral species during the analysis time provide information 
about the supersaturation extent and time (right panels in Figs. 2A and 2B). The supersaturation ratio 
(Rs) for glimepiride, determined as the ratio of maximum calculated concentration of neutral specie 
and S0, is about 125 and the duration of this supersaturation state (tsat) is about 6 min (Table 3).  
Since pioglitazone is an amphoteric molecule the titration could be started either in strong acidic 
(drug in H2X+ form) or in alkaline medium (X-). However, the complete dissolution of the compound 
was not achieved at pH 1.8, and thus all titrations were started at pH 11.5. Similar supersaturation 
times were found for glimepiride and pioglitazone, but with a lower supersaturation ratio (Table 3). 
This is consistent with the lower hydrogen-bonding capabilities and the lower polar surface of 
pioglitazone compared to glimepiride (Table 2). However, in contrast to glimepiride, the 
concentration profile of the neutral species shows for pioglitazone (Fig 2B, right panel) after about  2 
h a rise of the chasing equilibrium points, probably as a consequence of a solid form change into a 
more soluble one. 
Interestingly, the Bjerrum curves for sibutramine (Fig. 2C) clearly shows two different 
behaviors. First, as a non-chaser, the compound does not form a supersaturated solution and the 
experimental points follow the precipitation Bjerrum curve. However, at around pH 7.1–7.6 
sibutramine switches to a chaser behavior (with supersaturation). The change from non-chaser to 
chaser can be also monitored in the neutral species concentration-time profile: about 60 min after the 
beginning of the experiment there is an increment in the concentration of the neutral species in 
solution, followed by a sharp concentration drop and the establishment after about 80 min of the 
chasing equilibrium. The CheqSol software cannot accurately calculate the concentration of neutral 
species in the section between the concentration drop after the peak and about 80 min (Fig. 2C, right 
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panel), corresponding to pH values from 10 to 7.6 in the Bjerrum graph (left panel), because the 
molecular charge is close to zero and this affect the algorithms derived from charge and mass 
balances. After this period of transition a chaser behavior is observed. Interestingly, the intrinsic 
solubility calculated from cheqpoints is very similar to that immediately prior to the concentration 
peak when sibutramine behaved as non-chaser. The dual behavior of sibutramine allowed the 
measurement of intrinsic solubility through the non-chaser points using a curve fitting approach to 
the precipitation Bjerrum curve, but also as a chaser according to the crossing point method. Similar 
log S0 values were obtained in both cases, -5.28 ± 0.06 and -5.37 ± 0.14, respectively (average is 
presented Table 3). 
 
3.2. Solubility by shake-flask method 
3.2.1. Buffer and pH considerations 
The solubility-pH profile of each compound was studied by the shake-flask method using the 
recommended minimalist universal buffer (MS-MUB). This buffering system is expected to provide 
a reasonable buffer capacity over a wide pH range (2-12) with a nearly constant ionic strength of 
about 0.1 M, but avoiding the introduction of salt formers as chloride or phosphate anions (Avdeef et 
al., 2016). Nevertheless, depending on the nature of the starting solid or the one in equilibrium with 
the saturated solution (free species or salt) and the solubility of the charged species, the pH of the 
supernatant medium when equilibration is achieved might significantly differ from the initial pH of 
buffer (Avdeef et al., 2016; Shoghi et al., 2013). Figure 3 shows the pH variation observed between 
the pH measured after 4 hours of stirring and the initial pH of the buffer before the addition of the 
solid. Regarding glimepiride (Fig. 3A), in the acidic pH range, the initial sample and the solid 
collected was in both cases the neutral species (HA), and therefore a negligible pH variation was 
observed. When the ionic species (A-) started to play a relevant role in solution (pH > pKa) glimepiride 
took part in the acid-base equilibrium with the buffer, increasing the concentration of protons in 
solution and thus reducing the pH. However, the scarcely soluble HA still was the solid form in 
equilibrium, which moderated the pH decrease to only slight variations. However, at pH > 10 the 
solid phase in equilibrium was no longer the free acid (HA) and the precipitation of the salt (noted as 
C+A-(s) in the Fig. 3A, where C+ is a buffer component) shifted the equilibrium from HA to A- 
releasing H+ and thus significantly decreasing the solution pH.  
When the free pioglitazone (HX) was used only slight variations on pH were found in the 
equilibration step. At pH lower than pKa1 the formation of H2X+ consumed H+ and thus the pH became 
more basic, and the reversed trend was observed when X- was involved at pH > pKa2 (Fig. 3B). At 
this point and before discussing the effect on pH of pioglitazone hydrochloride as starting solid, it is 
needed to mention that only the free species (HX) was found as the solid phase in equilibrium in the 
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studied pH range. In all experiments the use of the hydrochloride salt of pioglitazone as starting solid 
(noted as H2X+C-(s) in Fig. 3B) produced a decrease in the solution pH. Two main causes were found 
to be responsible for the extent of this behavior. The first one was the amount of hydrochloride 
weighed. Since HX(s) was the only precipitating species, all chloride ions initially introduced with the 
sample and part of the protons were released in the solution. Consequently, the higher amount of 
hydrochloride salt, the higher the concentration of chloride in solution and the lower resulting pH. 
The second cause was related to the buffering capacity of the universal buffer used, which presents 
local minima at around pH 3, 6, and 9 (Fig. 3B).  
The pH variation for sibutramine (free base) was irrelevant in the basic range due to the low 
solubility of the neutral species, but there was a positive pH variation in acidic conditions because of 
the protonation of the base in solution (BH+(aq)) and the precipitation of the salt (BH+C-(s)) (Fig. 3C). 
Since the salt is quite soluble, the relatively high concentration of protonated base takes over the 
buffer capacity of MS-MUB resulting in shifts up to 3 pH units. Remarkably, the reversed trend was 
observed when sibutramine was initially introduced as hydrochloride salt. At pH << pKa the solid 
introduced and the precipitating species were of the same nature (BH+(aq) and BH+C-(s)) and thus the 
pH variation was negligible. At about neutral pH the precipitation of the free base (B(s)) was induced, 
reducing the pH as consequence of the deprotonation of BH+(aq).  
 
3.2.2. Solubility-pH profiles and identification of the collected solids 
Calculated solubility-pH profiles, as those shown in Fig. 1, are helpful in planning the 
experimental setup and measurement conditions of a shake-flask method (interesting pH range, 
amount of substance needed at each pH, expected concentrations and suitable quantification 
instruments…), but keeping in mind that estimated values are just an initial approximation.  
In this work, intrinsic solubilities (log S0) and the presence of aggregation reactions were 
deduced from fittings of experimental solubility data to the most appropriate models (Avdeef, 2007), 
and only solubilities obtained with the recommended MS-MUB buffer were taken into consideration 
for this purpose. However, MS-MUB is a complex buffering system and in the particular case of 
sibutramine several simpler buffers were selected to study the solubility of its salts. Table A.1 in the 
supplementary material summarizes these solubility data, reporting the measured pH at the end of the 




The solubility-pH profile of glimepiride is presented in Fig. 5. The starting weighed solid was 
the free acid for the whole studied pH range and it was confirmed by PXRD as the polymorph form 
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I, the most insoluble one (Bonfilio et al., 2012; Iwata et al., 1997). The diffractograms obtained for 
the solids collected in the acidic and neutral pH range confirmed the presence of form I, whereas in 
very alkaline solutions a new solid form was found, which does not correspond to any of the seven 
crystal forms reported in literature (Grell et al., 1998; Iwata et al., 1997; Tian and Zimmerman, 2017a, 
2017b, 2017c, 2017d, 2017e) (Table A.2, Figs. S.1-S.3). Based on the experimental solubility-pH 
profile in this basic region and the buffer components present in solution, we attribute this solid form 
to the sodium salt of glimepiride (this cation came from the strong base (NaOH) used to adjust the 
pH of the MS-MUB buffering system).  
Unexpectedly, the fittings of the experimental data to the theoretical Henderson-Hasselbalch 
equation (Eq. (1)) came to an apparent pKa for glimepiride that was about 0.5 pH units higher than 
the potentiometrically measured one, thus suggesting the influence of additional aggregation 
equilibria. After checking different fitting models, including the formation of neutral, anionic and 
mixed aggregates, the best fit was obtained when considering the formation a dimeric neutral 
aggregate of glimepiride ( 2 22HA H A , Eq. (2), case 1a in ref. (Avdeef, 2007)): 
apH p
0log log log(1+10 )
  KS S  (1) 
2 2H A
0 a 2 0log log log(1 /[H ]+2 )
  S S K K S  (2) 
where S0 is the intrinsic solubility of the monomeric species and 2 2H A2K  is the formation constant of 
the aggregate. Since glimepiride molecule has strong and self-complementary hydrogen bond donors 
and acceptors in its structure, it is plausible that a dimer is formed in solution. In fact, the crystal 
structure of its polymorphs shows strong self-assembling interactions involving the sulfonamide and 
urea groups present in the molecular structure (Endo et al., 2003; Gryl et al., 2011; Iwata et al., 1997). 
Consequently, as shown in Fig. 5, the apparent intrinsic solubility of glimepiride (log 
App
0S ) is about 
0.5 log units higher than log S0 due to aggregation reactions. The intrinsic solubility for glimepiride 
reported in this work is consistent with the experimental data measured by Seedher (Seedher and 
Kanojia, 2009) and Grbic (Grbic et al., 2010) research groups, provided that the aggregation constant 
of the dimeric neutral species is considered in the solubility model (Table 4). However, aggregation 
constants differ in more than 1.5 log units, which may indicate supersaturation (equilibration steps of 
24 h were reported in the cited papers, but information about sedimentation time after stirring step 
was not indicated). Additionally, the solubility value of -4.75 measured by Seedher and Kanojia at 
pH 7.4 using a 0.1 M phosphate buffer (Seedher and Kanojia, 2008) is in good agreement with our 
results at the same pH value. The lower apparent intrinsic solubility reported by Bergström and 
coworkers (log S0 = -7.83 ± 0.10 (Bergström et al., 2007)) contrasts with the ones reported in Table 
4, but it should be pointed out that this value was obtained after a double centrifugation process, 
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which might be prone to a potential sample loss due to adsorption in multiple transfers (Avdeef et al., 
2016). Interestingly, the intrinsic solubility determined by the potentiometric approach is about 0.8 
units higher, but more similar to the apparent value (log 
App
0S ). A possible explanation might be 
related to the CheqSol calculation algorithms, which do not foresee deviations from theoretical 
Hendersson-Hasselbalch equation (Eq. (1)) and consequently the formation of aggregated species in 
solution. At pH > 8.5 the sodium salt of glimepiride precipitates according to a calculated solubility 
product constant (pKsp) of 5.35 ± 0.01. 
 
3.2.2.2 Pioglitazone 
In the case of pioglitazone, the solid collected in the studied pH range (2-11) was in all cases 
the neutral species, independently whether the starting material was the free form or its hydrochloride 
salt, and its solubility-pH profile (Fig. 6) clearly matched the model for an amphoteric (non-
zwitterionic) compound with aggregation (apparently elevated solubility in the mid-pH region) 
(Avdeef, 2007): 
2 2H X
0 a1 a2 2 0log log log(1 [H ] [H ] 2 )
     S S K K K S  (3) 
where Ka1 and Ka2 are referred to the basic nitrogen of the pyridine and the acidic proton bound to the 
nitrogen of the thiazolidinedione group, respectively (Fig. 1 and Table 3). The fitted log S0 value was 
-6.98±0.04, about 1 unit lower in comparison to the intrinsic solubility potentiometrically determined 
in this work (-5.81±0.24), which better matches the apparent intrinsic solubility from the SF analysis 
(-5.70±0.05). Log 2 2H X2K , with a refined value of 7.98±0.12, corresponds to a dimer formation of the 
free ampholyte; however, the formation of colloids or nanoparticles could be also responsible for the 
solubility leveling in this mid-pH region (Gebauer et al., 2014; Irwin et al., 2015). The reported log 
S0 by Schönherr using a SiriusT3 instrument lies approximately in the middle of these two values 
(Table 3). The solubility measured in the present work at pH 7.4 is about 1 log unit lower than that 
determined by Seedher and Kanojia using a phosphate buffer (Seedher and Kanojia, 2008). However, 
in a later study (Seedher and Kanojia, 2009) these authors reported the solubility values of 
pioglitazone in the pH ranges 1.8-3.9 and 7.4-9.5 using glycine based buffers, which allow the 
calculation of a log S0 (using Eq. (3) with pKa values determined in this work) of -6.86±0.16, very 
consistent with our results. Similarly, Sugita and coworkers (Sugita et al., 2014) cited a solubility-pH 
profile carried out in the acidic range (1.2-6.8), which permit us to calculate a log S0 value of -





The most comprehensive study of this work was performed on sibutramine. Besides the aim of 
elucidating the effect of the starting material and the precipitating solid, we conducted a systematic 
research on the solubility of the positively charged species and its relation with the buffer counterions. 
It was found (Table A.1 and Fig 7A) that the nature of the solid precipitated was independent of the 
initial solid weighed (free base or hydrochloride salt). Only the neutral form was found at pH values 
above 5.8, but in more acidic media the solid collected was neither the neutral species nor the 
hydrochloride salt (Fig. 4). With the aim of identifying this salt, we carried out a series of shake-flask 
experiments with simple buffers prepared from acetic and trifluoroacetic acid (both constituents of 
the MS-MUB), but also hydrochloric and phosphoric acids, in order to study the salt formation of 
their respective anionic conjugate bases with the cationic sibutramine acid. The obtained results are 
presented in Figs. 7B and 7C. In the acidic pH range, different scenarios were observed: i) When TFA 
was used as buffering agent, independently of the initial form of sibutramine (free base or 
hydrochloride salt), the collected solid coincided with that precipitated at acidic media under MS-
MUB conditions. This suggests that MS-MUB induces the precipitations of the sibutramine TFA salt 
in acidic conditions, of which crystalline form was characterized by PXRD, DSC and TGA (Table 
A.3, Figs. S.4-S.6); ii) In nearly all cases in acidic conditions (with the formerly mentioned exception 
of TFA), hydrochloride salt was collected from the initially dissolved hydrochloride salt. It must be 
pointed out that sibutramineꞏHCl is quite soluble and thus the amount of chloride ions from the 
weighed sample may very well be higher than the concentration of buffering species in solution; iii) 
Starting with the free base (in order to minimize the concentration of chloride in solution), a new 
solid was collected when phosphate buffers were employed (Table A.3, Fig. S.7), attributed to 
sibutramine phosphate salt; iv) Hydrochloride and phosphate salts of sibutramine were more soluble 
than those with TFA;  v) In the pH region near pH 5.0 (close to the Gibbs pKa (Avdeef, 1998), i.e., 
“pHmax”) the solid phase in equilibrium can be a mixture of the uncharged form of the drug and 
TFA/phosphate salts. The fitting of the experimental points obtained with the MS-MUB buffer with 
the formation of TFA salt led to an intrinsic solubility value (log S0) for sibutramine of -5.62±0.02 , 
which is near the CheqSol result, and a solubility product constant (pKsp) for the TFA salt of 
3.23±0.03 . In a similar approximation, the pKsp for the hydrochloride salt was found to be 2.37±0.01 
and thus more soluble than the drug-TFA salt. Interestingly, in the pH range between 8 and 11 a slight 
positive deviation from the theoretical Hendersson-Hasselbalch behavior is observed (dashed line in 
Fig. 7), which suggests an interaction between the positively charged ethylenediamine (MS-MUB 
constituent) and the neutral sibutramine (log KB.enH = 1.54±0.28). The concentration of this aggregate 
reaches a maximum value at pH 9.4, when the molar fractions of neutral sibutramine (B) and the 
amphoteric ethylenediamine (enH+) are expected to be predominant (both about 80% according to 
14 




Shake-flask and CheqSol methods provide accurate, valuable and complementary information 
about the solubility behavior of compounds with acid-base properties. On the one hand, shake-flask 
is labor intensive and time consuming, but allows the solubility measurement of free species and their 
corresponding salts, even in the presence of aggregation or complexation reactions, and the solid 
precipitated can be easily collected and identified by powder X-ray diffraction. On the other hand, 
CheqSol is automated and provides additional data on supersaturation, but requires a previous 
accurate pKa determination, it is limited to intrinsic solubility (free acid or base) and assumes a 
Henderson-Hasselbalch behavior.  
Potentiometric measurements revealed that glimepiride (acid) and pioglitazone (ampholyte) 
were prone to supersaturation (chaser), as expected from their relatively high polar surface area and 
hydrogen-bonding capabilities. In contrast, sibutramine (base) was not expected to supersaturate and 
in fact it initially behaved as non-chaser, but later in the course of the titration it changed to a chaser 
behavior.  
Shake-flask experiments suggest the formation of dimeric neutral aggregates of glimepiride and 
pioglitazone and points out the effect of buffering species in the solubility of sibutramine salts at 
acidic pH, particularly the salt formed with TFA, a constituent of the recommended minimalist 
universal buffer (MS-MUB). The pH variation during the equilibration step depends on the initial 
form of the sample (free acid/base or salt) and the solid form and solubility of the precipitate. 
When aggregation reactions occur, as for glimepiride and pioglitazone, the intrinsic solubility 
calculated by the CheqSol method is similar to the apparent value determined by the shake-flask 
procedure. The potentiometric approach assumes a Henderson-Hasselbalch behavior, and thus the 
influence of additional aggregation equilibria is not considered. Fitting of the experimental shake-
flask solubility-pH data to the appropriate model allows the determination of intrinsic solubilities 
(lower than the apparent ones) and aggregation numbers and constants.  
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Table 1. Comparison between shake-flask and CheqSol methods. 
 Shake-flask method CheqSol method 
Accuracy - Gold standard. - Good correlation with SF. 
Solubility 
measurement 
- Thermodynamic (intrinsic 
solubility). 
- Thermodynamic and kinetic (extent 
and duration of supersaturation). 
Sample type - All. - Restricted to acid-base compounds. 
pH profile 
- Measurements performed at 
different pH values (including 
solubility of free species and 
salts, and aggregation reactions). 
- Requires accurate measurement of pKa 




- Large (depending on solubility). - Lower in comparison to SF. 
Laboratory 
equipment 
- Inexpensive apparatus (with the 
exception, perhaps, of centrifuge 
for phase separation and 
instrument for quantification). 
- Commercial titrator (SiriusT3, inForm, 
µDISS Profiler…). 
Throughput 
- Not suitable for screening. Labor 
intensive and time consuming. 
- Low-throughput. Automated. 
Solid 
identification 
- Sufficient solid can be easily 
collected for PXRD and 
identified 
- Changes in solubility can be observed 
in long-term analysis 
 
 













Glimepiride 9 3 490.62 3.4 6 133.0 
Pioglitazone 5 1 356.44 3.5 7 93.6 
Sibutramine 1 0 279.85 5.5 5 3.2 
*Advanced Chemistry Development (ACD/Labs) Software V11.02 embedded in SciFinder Scholar. 
 
 
Table 3. Potentiometrically determined acidity constants, intrinsic solubilities (S0), supersaturation 




 Thermodynamic solubility: log S0 (M)  Kinetic solubility 
  This work Literature  Rs tsat (min) 
Glimepiride  5.41 ± 0.06  -6.31 ± 0.12 -6.44(a)  124 ± 23 6 ± 1 
Pioglitazone  5.67 ± 0.09; 6.60 ± 0.09  -5.81 ± 0.24 -6.16(b)  10 ± 2 7 ± 2 
Sibutramine  8.74 ± 0.12  -5.33 ± 0.13 -  - - 
(a) (Narasimham and Barhate, 2011); (b)(Schönherr et al., 2015).  
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Table 4. Glimepiride shake-flask intrinsic solubility values (25 oC, log S in mol L-1) found in the 
literature and determined in the present work. Measured solubility values in acidic solutions (pH < 6) 
are labeled as log S0App.  These increased apparent solubility values are consistent with the formation 
of dimeric neutral aggregates, indicated by log K2H2A2.  
0logS  
App
0logS  2 2
H A
2logK  Comments 
-7.14 ± 0.02 -6.63 7.18 ± 0.21 This work 
-6.76 ± 0.07 -4.72 8.49 ± 0.09 pH 2.0-9.5; 0.05 M glycine; centrifuged, then filtered(a) 
-7.21 ± 0.03 -5.47 8.65 ± 0.06 pH 4.5-8.2, 0.2 M phosphate; filtered(b) 
-7.29   pH 6.5 (I=0.15M)(c), 37 oC value corr. to 25 oC(d) 
-7.83 ± 0.10   pH ~ 3; centrifuged 3 times(e); 21 oC corr. to 25 oC(d) 
(a)(Seedher and Kanojia, 2009); (b)(Grbic et al., 2010); (c)(Taupitz et al., 2013); (d)(Avdeef, 2015); 
(e)(Bergström et al., 2007).  
 
Table 5. Pioglitazone shake-flask intrinsic solubility values (25oC, log S in mol L-1) found in the 
literature and determined in the present work.  
0logS  Comments 
-6.98 ± 0.04 This work  
-6.63 ± 0.05 (a) 
-6.86 ± 0.16 Hydrochloride salt; pH 2.0-9.5; 0.05 M glycine; centrifuged, then filtered(b) 
-7.36 pH 2.4, 0.05 M phosphate, 3h incubation(c); 37 oC value corr. to 25 oC(d) 






Figure 1. Predicted solubility-pH profiles for glimepiride (acid) (A), pioglitazone (ampholyte) (B), 
and sibutramine (base) (C) by means of ACD/Labs GALAS (dashed lines) and p-DISOL-X software 
(solid lines). The latter profile was calculated for a solution containing 0.15 M NaCl and assuming 
that the salt solubility of the drug can be estimated by the “sdiff 3-4” approximation (Avdeef, 2008; 
Avdeef et al., 2000). 
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Figure 2. Mean molecular charge plots (Bjerrum curves and experimental data points, left panels) 
and neutral species concentration-time profiles (right panels) from CheqSol solubility measurements 





Figure 3. pH variation in the shake-flask method after 4h of stirring in relation to the initial aqueous 
buffer for glimepiride (A), pioglitazone (B), and sibutramine (C). The starting solid (free species or 
salt) is presented in the figure, together with the buffer capacity variation of the buffer (MS-MUB, 





Figure 4. Diffractrograms of different forms of glimepiride (A), pioglitazone (B), and sibutramine 




Figure 5. Shake-flask solubility-pH profile of glimepiride according to the collected solid. Dashed 




Figure 6. Shake-flask solubility-pH profile of pioglitazone according to the starting solid. Solid line 












Figure 7. Shake-flask solubility-pH profiles of sibutramine showing the effect of the starting solid 
and the buffering species on the finally collected solid. Dashed line represents the Henderson-
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Table A.1. Measured solubilities at different pH values by the shake-flask method using 
MS-MUB as buffering system (25 oC). 
Compound pHa,b log S (M)b Solid in equilibriumc 
Glimepiride 2.39 -6.60 Form I  
2.61 -6.60 -  
5.19 -6.56 Form I  
5.40 -6.39 Form I  
6.23±0.05 -6.26±0.18 -  
6.49±0.02 -6.07±0.15 Form I  
6.54±0.04 -6.11±0.11 -  
7.03±0.04 -5.64±0.04 -  
7.49±0.03 -5.22±0.03 -  
7.50±0.03 -5.12±0.01 -  
8.06±0.06 -4.59±0.06 Form I  
8.45±0.04 -4.27±0.04 -  
8.46±0.08 -4.43±0.23 -  
10.02±0.01 -3.97±0.02 Form I  
10.14±0.02 -3.96±0.01 Form I + unidentified phase  
10.90±0.02 -4.09±0.04 Form I + unidentified phase  
11.35±0.06 -4.11±0.02 Form I + unidentified phase 
Sibutramine 2.12 --1.91 TFA salt  
2.24 -1.86 TFA salt  
3.33 -1.68 TFA salt  
3.70±0.09 -1.54±0.02 TFA salt  
4.28±0.03 -1.61±0.10 TFA salt  
4.41 -1.64 TFA salt  
4.52±0.02 -1.07±0.08 Free base and unidentified phase  
4.76±0.20 -1.69±0.05 Freebase + TFA salt  
5.12±0.01 -1.71±0.03 Freebase + TFA salt  
5.14±0.07 -2.13±0.1 -  
5.29±0.02 -1.87±0.03 Freebase + TFA salt  
6.00±0.01 -2.72±0.05 Freebase  
6.99±0.03 -3.75±0.03 Freebase  
7.24±0.06 -4.09±0.05 Freebase  
8.01±0.11 -4.93±0.11 Freebase  
8.22±0.01 -5.06±0.03 Freebase  
8.52±0.12 -5.18±0.16 Freebase 
Sibutramine HCl 1.98±0.08 -1.76±0.09 TFA salt  
2.95±0.08 -1.78±0.02 TFA salt  
3.83±0.03 -1.50±0.09 Freebase + TFA salt  
3.99±0.07 -1.71±0.12 TFA salt  
4.75 -1.77 TFA salt  
4.81±0.04 -1.58±0.08 TFA salt 
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5.84±0.04 -2.65±0.03 -  
7.04±0.07 -3.76±0.04 Freebase  
7.39±0.09 -4.17±0.11 Freebase  
8.49±0.09 -5.12±0.27 -  
8.51±0.12 -5.08±0.11 Freebase  
9.40±0.12 -5.27±0.15 Freebase 
Pioglitazone 1.98 -3.43 Pioglitazone  
2.03 -3.34 Pioglitazone  
2.18 -3.31 Pioglitazone  
3.19±0.10 -4.06±0.09 Pioglitazone  
3.46±0.01 -4.37±0.04 -  
3.60 -4.71 -  
4.08 -4.96 Pioglitazone  
4.18±0.01 -4.97±0.03 -  
4.22±0.01 -5.19±0.01 Pioglitazone  
5.06±0.01 -5.62±0.04 - 
 5.01±0.02 -5.29±0.05 - 
 6.13±0.01 -5.59±0.07 - 
 7.00±0.04 -5.67±0.22 -  
7.92±0.02 -5.18±0.07 Pioglitazone  
8.04±0.01 -5.76±0.02 -  
9.19±0.01 -4.45±0.02 -  
9.25 -4.16 Pioglitazone  
9.87±0.01 -3.79±0.04 Pioglitazone  
10.96±0.05 -2.74±0.06 Pioglitazone  
11.04±0.02 -3.07±0.02 - 
PioglitazoneHCl 2.04 -3.16 -  
2.06 -2.94 Pioglitazone  
2.16±0.03 -3.51±0.03 -  
2.36 -3.13 -  
2.96 -4.31 -  
3.11 -3.48 -  
3.12±0.08 -4.50±0.14 -  
3.56 -4.77 -  
3.86±0.11 -5.03±0.09 -  
4.04±0.07 -5.08±0.07 Pioglitazone  
4.97±0.03 -5.20±0.12 -  
6.07±0.04 -5.54±0.08 -  
7.04±0.05 -5.62±0.14 -  
7.46±0.01 -5.17±0.07 -  
7.94±0.01 -5.52±0.05 -  
7.94±0.07 -5.36±0.06 -  
9.11±0.04 -4.42±0.04 -  
9.28±0.09 -4.31±0.11 -  
9.93±0.03 -3.56±0.05 - 
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9.99±0.01 -3.43±0.02 -  
10.35±0.01 -3.37±0.06 -  
11.08±0.06 -2.53±0.01 - 
a pH measured at the end of the sedimentation step, just before the phase separation by 
centrifugation.  
b Replicate measurements at similar pH values (standard deviations ≤ 0.1) are reported as 
their average log S ± standard deviation. On the contrary, individual replicates are 
presented instead. 
c Identification by PXRD. 
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Table A.2. PXRD peak lists (position, 2) of glimepiride crystal forms reported in 
published patents (, , ,  and ), simulated peak lists from crystal structures (forms I 
and II) and the new sodium salt phase characterized in this work. 
Glimepiride polymorphs reported New phase 
sodium salt α[1] β[2] γ[3] δ[4] ε[5] I[6] II[7] 
6.916     6.480 7.950 3.259 
7.200     10.970 10.527 9.785 
8.748  9.729  9.478 12.484 12.057 11.153 
10.378 10.895 10.033  10.110 13.140 12.503 12.767 
11.166 11.515 10.667 11.521 10.869 13.495 13.874 13.084 
14.017 12.316 12.995 14.231 11.447 13.863 14.389 14.399 
15.654 14.534 13.408 15.061 12.390 14.707 15.437 14.962 
17.107 14.923 17.854 16.529 13.044 16.756 15.934 15.216 
17.330 15.287 19.537 18.775 14.414 17.222 16.119 15.553 
18.349 16.277  20.536 15.694 18.206 16.967 15.828 
19.152 16.549  22.156 18.650 19.239 18.280 16.287 
21.103 17.645  30.579 18.984 20.713 18.621 17.998 
23.222 19.019  31.025 19.334 21.101 19.545 18.573 
23.662 21.952  31.708 21.828 21.348 19.823 19.052 
24.038 22.295   22.291 21.530 20.304 20.112 
24.332 23.539   22.805 22.030 21.234 20.354 
26.197 25.103   23.637 22.320 21.437 21.132 
27.055 26.261   24.693 22.994 21.535 21.900 
27.888 31.841   25.725 23.189 22.063 22.183 
28.178 33.044   27.188 23.332 22.849 22.780 
28.634 33.955   31.680 23.739 23.246 24.677 
29.085    34.046 25.295 23.781 25.156 
30.534     25.847 23.921 25.531 
33.804     26.426 24.014 26.581 
34.546     26.717 24.283 27.109 
35.048     28.945 24.384 31.071 
     29.510 25.158 31.397 
     30.322 27.946 31.510 
     31.939 29.454 34.087 
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Table A.3. PXRD peak list of the TFA sibutramine salt phase characterized in this 
work. 
Sibutramine TFA salt  Sibutramine phosphate salt 
Position 2 Relative intensity (%)  Position 2 Relative intensity (%) 
8.479 8.4  5.593 20.5 
9.917 14.1  5.855 100.0 
10.353 18.1  8.202 78.6 
11.588 21.8  11.471 17.3 
11.993 3.9  11.727 30.3 
13.386 16.0  12.789 37.6 
15.859 100.0  13.957 20.9 
16.977 63.8  14.431 64.7 
17.759 44.6  14.550 61.2 
18.048 17.6  16.453 52.7 
20.631 56.0  17.639 48.2 
20.806 22.5  18.014 46.9 
22.284 8.4  18.413 20.9 
22.500 28.1  18.887 22.9 
23.127 5.2  20.103 57.2 
23.391 55.6  20.318 40.6 
24.918 15.6  22.160 23.5 
26.928 9.8  22.734 40.2 
27.050 11.9  23.634 26.1 
28.890 8.6  24.510 21.8 
32.018 6.1  25.014 50.6 
35.989 8.3  25.745 19.5 
   28.775 28.0 
   29.540 18.3 
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Characterization of the solids 
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Left Limit 146,00 °C
Right Limit 299,55 °C 
Content 3,4914 %
0,1529 mg
Left Limit 29,44 °C
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Figure S.3: PXRD of glimepiride sodium salt 
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  normalized -46,39 Jg^-1
Peak 152,99 °C
Integral 23,67 mJ
  normalized 5,63 Jg^-1
Peak 149,20 °C
Integral -244,91 mJ
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Left Limit 134,94 °C
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The powder diffractogram was indexed and the lattice parameters were refined by means 
of the LeBail method, program Dicvol04[8], and the space group was determined from the 
systematic absences. The cell volume is compatible with 1 molecule of sibutramine and 
1 molecule of trifluoroacetic acid in the asymmetric unit, Z=4, (assuming a density value 
of 1.3). 
Figure S6: The XRPD diagram of Form SIBU-TFA has been indexed with the following 
monoclinic cell: a=17.439(2) Å, b=10.434(1) Å, c=11.422(1) Å, β= 102.230(5)º, 
V=2031.1(4) Å3 (Figures of Merit: M= 27, F= 70), according to systematic absences  
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The powder diffractogram was indexed and the lattice parameters were refined by 
means of the LeBail method, program Dicvol04[8], and the space group was 
determined from the systematic absences. The cell volume is compatible with 1 
molecule of sibutramine and 1 molecule of phosphoric acid in the asymmetric unit, 
Z=4, (assuming a density value of 1.2). 
Figure S7: The XRPD diagram of Form SIBU-phosphate has been indexed with the 
following triclinic cell: a=30.920(6) Å, b=19.905(3) Å, c=9.342(1) Å, α= 49.193(9)º, β= 
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